Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Granules India Limited ( (IN:GRANULES) ) has provided an update.
Granules India Limited has submitted a Monitoring Agency Report for the quarter ended March 31, 2026, detailing the utilization of proceeds raised through a preferential issue. The report, prepared by India Ratings & Research Private Limited in line with SEBI’s listing and capital-issue regulations, confirms that the company is formally tracking and disclosing how these funds are being used.
The filing underscores Granules India’s compliance with regulatory requirements on capital deployment transparency, which is important for shareholders and regulators assessing the governance around its preferential issue. By engaging an external monitoring agency and publicly filing the report with stock exchanges, the company reinforces its commitment to oversight of fundraising proceeds and investor confidence in its capital allocation practices.
More about Granules India Limited
Granules India Limited is an India-based pharmaceutical company involved in manufacturing and supplying active pharmaceutical ingredients, pharmaceutical formulation intermediates, and finished dosage forms. The company operates globally, serving generic and branded markets, and is listed on both the National Stock Exchange of India and BSE under the scrip code GRANULES/532482.
Average Trading Volume: 56,102
Technical Sentiment Signal: Buy
Current Market Cap: 172.2B INR
For a thorough assessment of GRANULES stock, go to TipRanks’ Stock Analysis page.